Patents by Inventor Jean-Yves Winum

Jean-Yves Winum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS
    Publication number: 20150150849
    Abstract: The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art.
    Type: Application
    Filed: February 4, 2015
    Publication date: June 4, 2015
    Applicants: STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO- CLINIC", UNIVERSITE MONTPELLIER 2 Sciences et Techniques
    Inventors: Philippe Lambin, Jean-Yves Winum, Claudiu Supuran
  • Cancer targeting using carbonic anhydrase isoform IX inhibitors
    Patent number: 8980932
    Abstract: The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1).
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: March 17, 2015
    Assignees: Stichting Maastricht Radiation Oncology “Maastro-Clinic”, Université Montpellier 2 Sciences et Techniques
    Inventors: Philippe Lambin, Jean-Yves Winum, Claudiu Supuran
  • CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY
    Publication number: 20140148400
    Abstract: Derivatized coumarin-based pharmaceutical compositions and methods to use them are provided. The compositions are characterized in that they inhibit the activity of tumor-related CAIX and CAXII to a greater degree than they inhibit the activity of CAI and CAII. The compositions can be used to suppress tumor growth and/or suppress tumor metastases in a mammal.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 29, 2014
    Applicants: METASIGNAL THERAPEUTICS INC., CNRS-DIRE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventors: Claudiu Supuran, Shoukat Dedhar, Fabrizio Carta, Jean-Yves Winum, Paul C. McDonald
  • CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS
    Publication number: 20130274305
    Abstract: The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1).
    Type: Application
    Filed: December 21, 2011
    Publication date: October 17, 2013
    Applicants: STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC", CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Philippe Lambin, Jean-Yves Winum, Claudiu Supuran
  • Histidinol dehydrogenase inhibitors, and use thereof as medicaments
    Patent number: 8372871
    Abstract: Compounds of general formula (I) below: are characterized in that A represents in particular a C5-C10 heterocyclic group, Y represents in particular a single bond, and B represents in particular an aryl or heteroaryl group.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: February 12, 2013
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Jean-Yves Winum, Jean-Louis Montero, Stephan Köhler
  • HISTIDINOL DEHYDROGENASE INHIBITORS, AND USE THEREOF AS MEDICAMENTS
    Publication number: 20120129907
    Abstract: Compounds of general formula (I) below: are characterized in that A represents in particular a C5-C10 heterocyclic group, Y represents in particular a single bond, and B represents in particular an aryl or heteroaryl group.
    Type: Application
    Filed: November 10, 2009
    Publication date: May 24, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Yves Winum, Jean-Louis Montero, Stephan Köhler